Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
RANCHO CORDOVA, Calif., April 25, 2018 -- Cesca Therapeutics Inc. (“Cesca” or the “Company”) (NASDAQ:KOOL) today announced that the Company will be exhibiting its full suite of cellular processing solutions, including CAR-TXpress™ for the semi-automated manufacture of CAR-T cell therapies, X-BACS™ for cell isolation and other X-Series™ kits, at the following cell therapy conferences in May:
- International Society of Cellular Therapy 2018 Annual Meeting
May 2 – 5, 2018
Booth: 322
Palais des congrès de Montréal
1001, Place Jean-Paul-Riopelle
Montreal, Canada
For more information: www.isct2018.com
- American Society of Gene and Cell Therapy 2018 Annual Meeting
May 16 – 19, 2018
Booth: 417
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
For more information: www.asgct.org/meetings-workshops/annual-meeting
- Phacilitate Automation Special Interest Group 2018
May 30 – 31, 2018
The Grove
Chandler’s Cross,
Watford WD3 4TG, Hertfordshire
London, UK
For more information: www.phacilitateautomation.com
About Cesca Therapeutics Inc.
Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing an automated, functionally-closed CAR-TXpress™ platform that addresses the critical unmet need for better cellular manufacturing and controls for the emerging CAR-T immunotherapy market. Cesca is an affiliated company of China-based Boyalife Group.
Company Contact:
Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
[email protected]
Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
[email protected]
